Shares of Concordia Healthcare Corp. (NASDAQ:CXRX) hit a new 52-week low on Thursday . The stock traded as low as $8.41 and last traded at $8.48, with a volume of 355,381 shares traded. The stock had previously closed at $8.71.

Several analysts have weighed in on the company. RBC Capital Markets reissued an “outperform” rating and set a $35.00 price objective on shares of Concordia Healthcare Corp. in a report on Tuesday, August 23rd. TD Securities reaffirmed a “hold” rating and issued a $14.00 price target (down from $20.00) on shares of Concordia Healthcare Corp. in a research note on Wednesday, August 17th. Zacks Investment Research cut Concordia Healthcare Corp. from a “hold” rating to a “strong sell” rating in a research note on Wednesday, August 17th. Canaccord Genuity set a $20.00 price target on Concordia Healthcare Corp. and gave the company a “buy” rating in a research note on Monday, August 15th. Finally, Goldman Sachs Group Inc. lowered their price target on Concordia Healthcare Corp. from $26.00 to $13.00 and set a “neutral” rating for the company in a research note on Monday, August 15th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $39.87.

The firm’s market cap is $417.32 million. The firm has a 50-day moving average of $13.96 and a 200-day moving average of $23.53.

Concordia Healthcare Corp. (NASDAQ:CXRX) last released its quarterly earnings data on Friday, August 12th. The company reported $1.38 earnings per share for the quarter, hitting the consensus estimate of $1.38. The business earned $231.70 million during the quarter, compared to analysts’ expectations of $229.76 million. The company’s quarterly revenue was up 208.1% on a year-over-year basis. Equities analysts expect that Concordia Healthcare Corp. will post $5.35 EPS for the current year.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.